文献速递炎症性肠病

减重手术或减重药物与肥胖患者新发炎症性肠病风险的关系

Risk of de-novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications.
PubMed 文献 · Aliment Pharmacol Ther · 2020-04-21

BACKGROUND: An association between bariatric surgery and development of de-novo inflammatory bowel disease (IBD) has been observed. AIM: To evaluate further the association among bariatric surgery, weight loss medications, obesity and new-onset IBD.…

要点

  • 减重手术或减重药物暴露的肥胖患者新发IBD患病率低于持续肥胖对照。
  • 奥利司他是唯一未显示降低新发IBD风险的减重药物。
  • 肥胖与未有效管理的肥胖可能是新发IBD的危险因素。

核心结论

  • 接受减重手术或减重药物治疗的肥胖患者新发IBD风险低于未接受这些干预的持续肥胖对照。
  • 数据提示肥胖及未有效管理的肥胖是新发IBD的危险因素。

研究设计与样本

  • 使用Explorys这一符合美国健康保险携带与责任法案的人群数据库进行回顾性分析,时间范围为1999至2018年。

主要发现

  • 减重手术组新发IBD患病率为7.72/1000例,减重药物组为7.22/1000例,持续肥胖对照组为11.66/1000例,P<0.0001。
  • 除奥利司他外,各类减重手术和减重药物均与一致的新发IBD风险降低相关。
  • 奥利司他与持续肥胖对照相比未显示新发IBD风险降低。

临床怎么用

  • 对于肥胖患者,减重手术或减重药物干预可能与较低的新发IBD风险相关,但需进一步研究确认。
  • 奥利司他在降低新发IBD风险方面未显示与其它减重干预一致的效果。

局限性

  • 原文指出需进一步研究确认这些观察结果并理解潜在机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An association between bariatric surgery and development of de-novo inflammatory bowel disease (IBD) has been observed. AIM: To evaluate further the association among bariatric surgery, weight loss medications, obesity and new-onset IBD. METHODS: Using Explorys, a population-based Health Insurance Portability and Accountability Act compliant database, we estimated the prevalence of de-novo IBD among patients treated with bariatric surgery (Roux-en-Y gastrojejunostomy, laparoscopic sleeve gastrectomy or gastric banding) (n = 60 870) or weight loss medications (orlistat, phentermine/topiramate, lorcaserin, bupropion/naltrexone and liraglutide) (n = 193 790) compared with obese controls (n = 5 021 210), between 1999 and 2018. RESULTS: The prevalence of de-novo IBD was lower among obese patients exposed to bariatric surgery (7.72 per 1000 patients) or weight loss medications (7.22 per 1000 patients) compared with patients with persistent obesity not exposed to these interventions (11.66 per 1000 patients, P < 0.0001). The risk reduction for de-novo IBD was consistent across bariatric surgeries and weight loss medications with the exception of orlistat which was not associated with a reduction in risk for de-novo IBD compared with the persistent obese control cohort. CONCLUSION: Obese patients undergoing treatment with bariatric surgery or weight loss medications are at a lower risk for developing de-novo IBD compared with persistently obese controls not exposed to these interventions. These data suggest that obesity and ineffective management of obesity are risk factors for de-novo IBD. Further research is needed to confirm these observations and understand potential mechanisms.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kochhar GS, Desai A, Syed A, et al. Risk of de-novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications. Aliment Pharmacol Ther. 2020. PMID: 32319111. doi:10.1111/apt.15721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。